8-K: Dentsply Sirona Reports Disappointing Fourth Quarter and Full Year 2024 Results, Provides Cautious 2025 Outlook

Dentsply Sirona's 2024 results reveal a net loss and sales decline, with a cautious outlook for 2025 anticipating further organic sales decrease.

Summary

• Dentsply Sirona reported a net sales decrease of 4.3% for the full year 2024, totaling $3,793 million.
• Organic sales decreased by 3.5%, which includes a 1.2% negative impact from Byte sales.
• The company experienced a GAAP net loss of $910 million, or $4.48 per share, for the full year.
• Adjusted EPS for the full year was $1.67, compared to $1.83 in the previous year.
• Fourth quarter net sales decreased by 10.6% to $905 million, with organic sales down 10.7% including a 6.0% Byte sales impact.
• The GAAP net loss for the fourth quarter was $430 million, or $2.16 per share.
• Adjusted EPS for the fourth quarter was $0.26, compared to $0.44 in the fourth quarter of 2023.
• For 2025, the company anticipates net sales in the range of $3.50 billion to $3.60 billion, with organic sales declining by 4.0% to 2.0% including a 2% Byte sales impact.
• Adjusted EPS for 2025 is expected to be in the range of $1.80 to $2.00.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the reported net losses, sales declines, and cautious outlook for 2025. While there are some positive aspects, the overall tone is one of concern and challenges.

Positives

• Full year 2024 operating cash flow was $461 million, compared to $377 million in the prior year, driven by improved inventory management and cash collections.
• The company returned $376 million to shareholders through dividends and share repurchases in 2024.
• Improvements in Q4 included a return to growth in Europe and imaging globally, as well as continued growth of Wellspect Healthcare and SureSmile.

Negatives

• Full year 2024 net sales decreased by 4.3% to $3,793 million.
• The company reported a GAAP net loss of $910 million, or $4.48 per share, for the full year 2024.
• Fourth quarter net sales decreased by 10.6% to $905 million.
• The GAAP net loss for the fourth quarter was $430 million, or $2.16 per share.
• Organic sales decreased by 3.5%, which includes a 1.2% negative impact from Byte sales.
• Fourth quarter organic sales decreased by 10.7% including a 6.1% Byte sales impact.
• Non-cash charges for the impairment of goodwill and other intangible assets were ($870) million net of tax, or ($4.27) per share in 2024.
• Operating cash flow in the fourth quarter of 2024 was $87 million, compared to $160 million in the fourth quarter of 2023, primarily due to unfavorable timing of working capital adjustments.

Risks

• Weakened demand and competitive pressures in implants and equipment contributed to goodwill and intangible asset impairments.
• The company wrote off the Byte trademark based on a determination that the trademark will not be used in the future aligners operating model.
• The company anticipates the external environment to remain broadly unchanged in 2025.
• The 2025 outlook includes a (2%) Byte sales impact.

Future Outlook

The company anticipates net sales in the range of $3.50 billion to $3.60 billion for 2025, with organic sales declining by 4.0% to 2.0%. Adjusted EPS is expected to be in the range of $1.80 to $2.00.

Management Comments

• In 2024 we made meaningful progress on our transformational agenda to strengthen our foundation and position the company for long-term success.
• While we were pleased to see improvement in several areas of the business, Byte, persistent macro pressures and competitive dynamics negatively impacted Q4 and 2024 full year results.
• In 2025, we anticipate the external environment to remain broadly unchanged, with our transformational initiatives driving EBITDA margin expansion and adjusted EPS growth.
• As we look forward, we believe our differentiated portfolio, robust innovation pipeline, and increased focus on customer experience and organizational efficiency, position us to capitalize on strategic opportunities and create value for our stakeholders.

Industry Context

The dental industry is facing headwinds from macroeconomic pressures and competitive dynamics, impacting companies like Dentsply Sirona, particularly in segments like orthodontics and implants. The company's focus on transformation and efficiency reflects a broader trend in the industry to adapt to changing market conditions.

Comparison to Industry Standards

• Dentsply Sirona's performance can be compared to other major players in the dental industry, such as Align Technology (ALGN) in the orthodontics space and Straumann in the implant sector.
• Align Technology, while focused on clear aligners, has also faced challenges in a competitive market, but has shown stronger growth in certain regions.
• Straumann, a leader in dental implants, has generally demonstrated more resilient performance in its core market compared to Dentsply Sirona's Orthodontic and Implant Solutions segment.
• The Byte write-off highlights the challenges in the direct-to-consumer aligner market, where competition is intense and marketing costs are high.

Stakeholder Impact

• Shareholders will be impacted by the net losses and sales declines, as well as the cautious outlook for 2025.
• Employees may be affected by the company's restructuring initiatives and focus on organizational efficiency.
• Customers may see changes in product offerings and customer experience as the company implements its transformational agenda.
• Suppliers and creditors may be impacted by the company's financial performance and strategic decisions.

Next Steps

• The company will continue to focus on its transformational agenda and strategic initiatives.
• Management will host an investor conference call and live webcast on February 27, 2025.
• The company will pay a quarterly cash dividend on April 11, 2025, to holders of record as of March 28, 2025.

Key Dates